Abstract
Interleukin 12 (IL-12) is a disulfide-linked heterodimer molecule produced predominantly by professional antigen presenting cells. It promotes the induction of sundry biological effects with significant relevance to antitumor immunity, such as enhancing a T H 1 helper response, an in vivo antiangiogenic effect, induction of adhesion molecules that assist in lymphocyte homing to sites of tumor growth, and a direct stimulatory effect on both T-cells and NK cells. We tested the efficacy of an antimetastatic vaccine composed of autologous murine D122 cells transfected with both subunits of IL-12 cDNA to express biologically-active IL-12 molecule. Expression of IL-12 by D122 cells significantly reduced their tumorigenicity and metastatic potential in immunocompetent syngeneic hosts. Furthermore, vaccination of mice with 2 × 106 irradiated IL-12-transfected D122 cells engendered a protective CTL response which rejected a subsequent challenge with parental D122 cells and eradicated lung micrometastasis in animals whose primary tumors have been surgically removed. The antitumor effects of IL-12 were mediated primarily by its ability to induce gIFN expression in vivo. CD8 + T-cells as well as NK cells were crucial in the execution of the antitumor effects of IL-12. These results suggest that autologous tumor cells expressing IL-12 by gene transfer are a potent antitumor vaccine able to induce a systemic immune response against poorly immunogenic and spontaneously metastatic tumors. ©Lippincott Williams & Wilkins
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dranoff G, Jaffee E, Lazenby A, et al.,1993, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA,90, 3539-43.
Colombo MP and Rodolfo M, 1995, Tumor cells enginnered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials ? Cancer Immunol Immunother, 41, 265-70.
Schoenhaut DS, Chua AO, Wolitzky AG, et al.,1992, Cloning and expression of murine Il-12. J Immunol,148, 3433-40.
Banks, RE, Patel, PM and Selby PJ, 1995, Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer, 71, 655-9.
Tahara H Lotze MT, 1995, Antitumor effects of interleukin 12 (IL-12): applications in the immunotherapy and gene therapy of cancer. Gene Therapy, 2, 96-106.
Romagnani S, 1995, Biology of human TH1 and TH2 cells. Clinical Immunol, 15, 121-9.
Trinchieri G, 1993, Interleukin 12 and its role in the generation of TH1 cells. Immunol Today, 14, 335-338.
Voest EE, Kenyon BM, O'Reilly MS, et al.,1995, Inhibition of angiogenesis in vivoby interleukin 12. J Natl Cancer Inst, 87, 581-6.
Ogawa M, Tsutsui T, Zou J, et al.,1997, Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. Cancer Res, 57, 2216-22.
Kim JJ, Ayyavoo V, Bagarazzi ML, et al.,1997, In vivoengineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol, 158, 816-26.
Tahara H, Zeh III HJ, Storkus WJ, et al.,1994, Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Res, 54, 182-9.
Caruso M, Pham-Nguyen K, Kwong Y, et al.,1996, Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA,93, 11302-11306.
Porgador A, Bannerji R, Watanabe Y, et al.,1993, Antimetastatic vaccination of tumor-bearing mive with two types of IFN-γ gene-inserted tumor cells. J Immunol, 150, 1458-70.
Gately, MK and Chizzonite, R, 1992, Measurement of human and mouse interleukin-12. In: Coligan, JE, Kruisbeek, AM, Margulies, DH, Shevach, EM and Strober, W., eds. Current Protocols in Immunology,. New York: Green Publishing and Wiley-Interscience, pp. 6.
Porgador A, Tzehoval E, Katz A, et al.,1992, IL-6 gene transfection into 3LL tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res, 52, 3679-86.
Brunda MJ, Luistro L, Warrier RR, et al.,1993, Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med, 178, 1223-30.
Takeda K, Seki S, Ogasawara K, et al.,1996, Liver NK1.1+ CD4+ αβ T cells activated by IL-12 as a major effect in inhibition of experimental tumor metastasis. J Immunol, 156, 3366-73.
Hashimoto W, Takeda K, et al.,1995, Cytotoxic NK 1.1 Ag+ αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol, 154, 4333-40.
Nastala CL, Edington HD, McKinney TC, et al.,1994, Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol, 153, 1697-706.
Martinotti A, Stoppacciaro A, Vagliani M, et al.,1995, CD4 T cells inhibit in vivothe CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin 12 genes. Eur J Immunol, 25, 137-46.
Lamont AG, Adorini L, 1996, IL-12: A key cytokine in immune regulation. Immunol. Today, 17, 214-7.
Pardoll DM, 1995, Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol, 13, 399-415.
Cavallo F, Signorelli P, Giovarelli M, et al.,1997, Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Ins, 89, 1049-58.
Rodolfo M, Zilocchi C, Melani C, et al.,1996, Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens: Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol, 157, 5536-42.
Schoenhaut DA, Chua A, Wolitzky A, et al.,1992, Cloning and expression of murine IL-12. J Immunol, 148, 3433-40.
D'Andrea A, Rengaraju M, Valliante N, et al.,1992, Production of NKSF (IL-12) by peripheral blood mononuclear cells. J Exp Med, 180, 211-22.
Zitvogel L, Tahara H, Robbins BD, et al.,1995, Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically-engineered fibroblasts. J Immunol, 155, 1393-403.
Porgador A, Tzehoval E, Vadai E, et al.,1995, Combined vaccination with major histocompatibility class I and interleukin 2 gene-transdused melanoma cells synergises the cure of postsurgical established lung metastases. Cancer Res, 55, 4941-9.
Gately MK, Warrier RR, Honasoge S, et al.,1994, Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocytes activity and induces production of IFN-γ in vivo. Int Immunol, 6, 157-67.
Manetti R, Gerosa F, Giudizi MG, et al.,1994, Interleukin 12 induces stable priming for interferon γ (IFN-γ) production during differentiation of human T helper (Th) cells and transient IFN-γ production in established Th2 cell clones, J Exp Med, 179,1273-83.
Seder RA, Gazzinelli R, Sher A and Paul WE, 1993, IL-12 acts directly on CD4+ T cells to enhance priming for IFN-γ production and diminishes IL-4 inhibition of such priming. Proc Natl Acad Sci USA, 90, 10188-93.
Tannebaum CS, Wicker N, Armstrong D, et al.,1996, Cytokine and chemokine expression in tumors of mice recieving systemic therapy with IL-12. J Immunol, 156, 693-9.
Zou J-P, Yamamoto N, Fuji T, et al.,1995, Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int Immunol, 7,1135-45.
Fallarino F, Uyttenhove C, Boon T and Gajewski TF, 1996, Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol, 156, 1095-100.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Popovic, D., El-Shami, K.M., Vadai, E. et al. Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine Interleukin 12. Clin Exp Metastasis 16, 623–632 (1998). https://doi.org/10.1023/A:1006508413070
Issue Date:
DOI: https://doi.org/10.1023/A:1006508413070